ArticleTransfusion2024
Parvovirus B19 rebound outbreak 2024 and implications for blood- and plasma-product safety.
Article in Transfusion, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- The specifications of blood components for neonatal transfusion: a European study and critical review.Pediatric research · 2026Article
- Parvovirus B19-induced aplastic crises in children with hereditary spherocytosis in the Czech Republic: multicentre retrospective study.BMC infectious diseases · 2026Article
- Article
- Incidence of parvovirus B19 among Hungarian blood donor population during COVID-19 restrictions and the subsequent B19 epidemic of 2024.Epidemiology and infection · 2026Article
- Insights into parvovirus B19 clinical and virological dynamics among blood donors.Le infezioni in medicina · 2026Article
- Molecular and serologic analysis of linked blood donor and recipient samples to rule out transfusion-transmitted parvovirus B19 infection.Frontiers in public health · 2026Article
- Long-Term Retrospective Analysis of Parvovirus B19 Infections in Blood Donors (2012-2024): Significant Increase in Prevalence Following the SARS-CoV-2 Pandemic.Diagnostics (Basel, Switzerland) · 2025Article
- Is parvovirus B19 infection upsurge in 2023-2024 associated with adverse pregnancy outcome?Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology · 2025Article
- Congenital Parvovirus B19 During the 2024 European Resurgence: A Prospective Single-Centre Cohort Study.Pathogens (Basel, Switzerland) · 2025Article
- An Epidemic of Parvovirus B19-Induced Aplastic Crises in Pediatric Patients with Hereditary Spherocytosis Following the COVID-19 Pandemic: A Single-Center Retrospective Study.Children (Basel, Switzerland) · 2025Article
- Compelling Increase in Parvovirus B19 Infections: Analysis of Molecular Diagnostic Trends (2019-2024).Viruses · 2025Article
- Epidemiology of Parvovirus B19 Infection In an Italian Metropolitan Area, 2012-2024: COVID-19 Pre-Pandemic, Pandemic and Post-Pandemic Trends.Journal of medical virology · 2025Article
- Review
- Parvovirus B19 rebound outbreak 2024 and implications for blood- and plasma-product safety.Transfusion · 2024Article
- Surveillance of blood donors detects an exceptional Parvovirus B19 outbreak in Switzerland in 2023/2024.Blood transfusion = Trasfusione del sangueArticle
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSince the beginning of 2024, several European countries reported unusually high numbers of Human parvovirus B19 (B19V) infections. An increase in B19V incidence rate might have implications for blood products for direct transfusion, however, large data sets for analysis of this outbreak are missing. STUDY DESIGN AND
methodsB19V nucleic acid testing (NAT) of plasma donations collected between June 2018 and May 2024 from mainly Central European countries (n = 9.6 million) and the United States (n = 70.7 million) was done to the individual donation level.
resultsIn Central Europe, there was a marked increase in B19V incidence from November 2023 onwards, which peaked in April 2024 with a 33-fold higher than average B19V incidence versus before the COVID-19 pandemic. In the United States, a similar trend was seen, with a yet still 6-fold lower increase than in Europe at the same time. The largest increase in B19V positivity was seen in the youngest plasma donor cohort. DISCUSSION: A B19V infection gap during the COVID-19 pandemic is likely the basis for the rebound outbreak in 2023/2024, particularly in Europe. B19V NAT of millions of plasma donations provides for large scale numbers to solidify available epidemiology insight, and to support adequate risk assessments. Based on the situation it may be prudent to consider B19V NAT for blood components specifically directed towards transfusion to higher risk recipients, or alternatively, preselecting B19V seropositive individuals or advanced age donors at higher likelihood of seropositivity and thus lower risk of virus transmission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.